23 April 2026
\n \n \n \nEntelo Bio, an AIxBio company focused on the biology of movement and ageing, emerges from stealth today with a total of $4 million in funding, led by Ananda Impact Ventures, with participation from The Creator Fund and US and European bio- and tech-focused angels.
\n \n\n \n \n19 April 2026
\n \n \n \nENA101 targets DARKFOX\u00ae, a novel, cancer\u2011specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt\u2011ORF) within FOXM1. DARKFOX was discovered and validated using Enara\u2019s proprietary EDAPT\u00ae platform and represents a new class of highly tumour-specific targets derived from the dark proteome.
\n \n\n \n \n15 April 2026
\n \n \n \nAlethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX\u2011011, a first\u2011in\u2011class, mutation\u2011agnostic antibody with potential to disrupt the $2B Essential Thrombocythemia (ET) market. Alongside this, the Company announces the appointment of Steve R. Coats, PhD, a veteran biologics leader, as Chief Development Officer, to advance the ATX-011 programme towards IND submission, targeted for Q1 2027.
\n \n\n \n \n29 March 2026
\n \n \n \nBioarchitech, Oxford, UK, an immuno-oncology therapeutics start-up company announces that it has secured a material license from the European Collection of Authenticated Cell Cultures (ECACC), UKHSA for a mammalian cell line to be developed as a scalable and high yield viral manufacturing platform and for the vector backbone of BA-V151, a preclinical stage candidate being developed as a treatment for metastatic cancers.
\n \n\n \n \n29 March 2026
\n \n \n \nPGN-EDODM1 was generally well-tolerated, with all adverse events being mild or moderate, and no serious adverse events reported. The mean splicing correction observed with PGN-EDODM1 (n=6) was 7.3%, compared to 6.8% for the placebo (n=2). Excluding one outlier patient, the treatment group showed a mean splicing correction of 22.9% (n=5). Promising trends were seen in vHOT in the PGN-EDODM1 treated group. The company is on track to report clinical data from the 10 mg/kg multiple dose cohort in the second half of 2026, with sufficient cash expected to fund operations into the second half of 2027.
\n \n\n \n \n29 March 2026
\n \n \n \nThe BioEscalator is proud to be a founding signatory of Equinox (Equitable Innovation Oxford), a new initiative connecting research, business and communities to accelerate innovation and deliver inclusive growth in Oxford and the wider region.
\n \n\n \n \n18 March 2026
\n \n \n \nWe are delighted to welcome Professor Paul Leeson to our Management Board - an expert in cardiovascular imaging and preventive cardiology, entrepreneur and supporter of translational research and spin-out creation.
\n \n\n \n \n18 March 2026
\n \n \n \nEnara Bio, a pioneer in Dark Antigen\u00ae discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its lead clinical candidate, ENA101, a first-in-class bispecific T cell engager (TCE) targeting DARKFOX\u00ae, a novel cancer-specific Dark Antigen discovered with Enara\u2019s EDAPT\u00ae platform.
\n \n\n \n \n11 March 2026
\n \n \n \nStay informed with the latest BioEscalator updates, tenant and alumni news in the Spring 2026 edition of the BioEscalator Bulletin.
\n \n\n \n \n10 March 2026
\n \n \n \nProfessor Dame Molly Stevens joins as a Non-Executive Director and University representative. Professor Richard Hobbs also joins as a Non-Executive Director. Simon Boddie, the Chief Financial Officer of the University of Oxford, steps down.
\n \n\n \n \n8 March 2026
\n \n \n \nQ: What kind of biosciences event features being an actress, being a cool kid, twin babies, presenting to empty lecture theatres, offices with no toilets for women, and mentorship schemes that don\u2019t work? A: The BioEscalator\u2019s celebration of International Women\u2019s Day 2026.
\n \n\n \n \n5 March 2026
\n \n \n \n\"We decided to skip the engagement and just get married\" \u2013 that\u2019s how Hutano Diagnostics\u2019 CEO Atherton Mutombwera describes his company\u2019s acquisition by EDx Medical in 2023. The meeting of minds between him and the purchaser\u2019s CEO, Dr Mike Hudson, was the culmination of six years of hard work by Atherton developing multiplex lateral flow diagnostics based on aptamers.
\n \n\n \n \n4 March 2026
\n \n \n \nPending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics\u2019 innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.
\n \n\n \n \n3 March 2026
\n \n \n \nInfinitopes has been featured in a recent blog post by VC Amplify Partners, highlighting its work to prevent cancer recurrence and its approach to advancing precision cancer vaccines.
\n \n\n \n \n24 February 2026
\n \n \n \nU-Ploid Biotechnologies has initiated a new collaborative research study with San Diego Fertility Center (SDFC) and Nova Genomics, marking an important translational step in the company\u2019s programme to address the biological causes of age-related infertility.
\n \n\n \n \n20 February 2026
\n \n \n \nOn its recent visit to Oxford, leading biotech sector commentator Biotech TV had a fascinating and wide-ranging conversation with Dr Jonathan Kwok, the CEO of BioEscalator tenant Infinitopes.
\n \n\n \n \n18 February 2026
\n \n \n \nThe pioneering partnership combines cyanobacteria-based oral delivery with AI-driven robotics to transform how life-saving biologics reach patients.
\n \n\n \n \n16 February 2026
\n \n \n \nApprentices are a vital part of BioEscalator life, and we always enjoy celebrating their achievements and impact in National Apprenticeship Week.
\n \n\n \n \n16 February 2026
\n \n \n \nDr Morrow brings deep expertise in immunology, oncology, and pharmacology, with a strong track record of advancing innovative pipelines from discovery to the clinic. The appointment\r\nreflects growing momentum at Nucleome following the nomination of the first preclinical development candidate, lead candidate NTP464, which is progressing towards IND-enabling studies.
\n \n\n \n \n10 February 2026
\n \n \n \nU-Ploid Biotechnologies (U-Ploid), an Oxford-based biotechnology company pioneering first-in-class therapeutics for reproductive health, today announced the appointment of Tim Stonehouse as the company\u2019s first in-house Head of Regulatory Affairs.
\n \n\n \n \n